STAT

Opinion: I hope the departure of ‘tech-savvy’ Gottlieb won’t undo progress at the FDA

Health care has a different look than it did a decade ago. @SGottliebFDA recognized the need for the agency to pivot in response to these external pressures.
Source: Justin Sullivan/Getty Images

We’re about to lose the most tech-savvy commissioner of the Food and Drug Administration in recent memory. At its core, the FDA is about keeping people safe. But Scott Gottlieb helped transform the agency’s top role from “custodian of safety” to “advocate of innovation” by pushing for progress and refusing to let outdated regulations stand in his way. I hope his replacement doesn’t backpedal to the agency’s more conservative past and undo the progress that he’s made.

Gottlieb, who on Tuesday, has left in his nearly two-year stint at the agency. Under his forward-looking direction, the FDA has proposed several frameworks to streamline health care’s adoption of new technologies and has even received industry

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min readIntelligence (AI) & Semantics
STAT+: Q&A: Defining Responsible AI In Health Care, With CHAI CEO Brian Anderson
CHAI CEO Anderson wants to build public trust in AI and empower patients and providers to have more informed conversations.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Approval For Sarepta Drug, MSF Closing Access Campaign And More
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement over access to several cystic fibrosis treatments, capping an end to a controversial, long-running saga:
STAT2 min read
STAT+: Pharmalittle: We’re Reading About EMA Plans For GLP-1 Shortages, Walgreens Store Closings, And More
The European Medicines Agency and member countries announced several steps to address shortages of GLP-1 drugs.

Related Books & Audiobooks